AIM ImmunoTech is trading 10.7% up at $0.26 on what appears to be a light-liquidity rebound following recent weakness.
- The move occurs in the absence of fresh company announcements, clinical updates, or analyst calls this morning.
- The gain stands out against a declining biotech sector and broader markets that are only trading modestly higher.
- Today's jump is likely driven by technical trading and thin volume rather than any change in company fundamentals.